Daniel G. Anderson Ph.D.
Net Worth
Last updated:
What is Daniel G. Anderson Ph.D. net worth?
The estimated net worth of Dr. Daniel G. Anderson Ph.D. is at least $2,402,520 as of 2 Jun 2021. He has earned $2,000,000 from insider trading and has received compensation worth at least $402,520 in Sigilon Therapeutics, Inc..
What is the salary of Daniel G. Anderson Ph.D.?
Dr. Daniel G. Anderson Ph.D. salary is $100,630 per year as Co-Founder & Member of Scientific Advisory Board in Sigilon Therapeutics, Inc..
How old is Daniel G. Anderson Ph.D.?
Dr. Daniel G. Anderson Ph.D. is 55 years old, born in 1970.
What stocks does Daniel G. Anderson Ph.D. currently own?
As insider, Dr. Daniel G. Anderson Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) | Co-Founder & Member of Scientific Advisory Board | 2,022,222 | $0 | $0 |
What does Sigilon Therapeutics, Inc. do?
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Daniel G. Anderson Ph.D. insider trading
Sigilon Therapeutics, Inc.
Dr. Daniel G. Anderson Ph.D. has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 200,000 units of SGTX stock worth $2,000,000 on 2 Jun 2021.
As of 2 Jun 2021 he still owns at least 2,022,222 units of SGTX stock.
Sigilon Therapeutics key executives
Sigilon Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Daniel G. Anderson Ph.D. (55) Co-Founder & Member of Scientific Advisory Board
- Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD (76) Co-Founder & Member of Scientific Advisory Board
- Dr. Rogerio Vivaldi Coelho M.D., MBA (61) Pres, Chief Executive Officer & Director